ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

... and diabetes drug from Ipsen

July 24, 2006 | APPEARED IN VOLUME 84, ISSUE 30

Roche will license, develop, and market Ipsen's antidiabetes drug BIM 51077, a glucagon-like peptide 1 (GLP-1) analog. Roche decided to exercise its option under a 2003 agreement following favorable Phase I and II clinical trials. Roche will pay Ipsen $71 million up front and an additional $3.8 million after closing of Ipsen's 2006 financial statements. Additional milestone payments to Ipsen could total $214 million.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment